![Thumbs Up on Amgen's T-VEC to Treat Melanoma; Is it Local Therapy for Systemic Disease?](https://cdn.cancerletter.com/media/2024/01/29040329/41-17-NCIsRichard-Sherry.jpg)
![Thumbs Up on Amgen's T-VEC to Treat Melanoma; Is it Local Therapy for Systemic Disease?](https://cdn.cancerletter.com/media/2024/01/29040329/41-17-NCIsRichard-Sherry.jpg)
Cover Story
NCI surgeon Richard Sherry tried unsuccessfully to refocus FDA's approval question.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop